Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
69 stopped studies mapped to Gastric Carcinoma and descendants · 97% state a reason
Over the 69 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API ().
reasonMatches| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06882746 | A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon,… | Phase 1 | terminated | Mar 19, 2025 | Boehringer Ingelheim | Sponsor decision | Sponsor / business decision |
| NCT04111172 | A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma | Phase 2 | suspended | Oct 1, 2019 | Thomas Jefferson University | Protocol is with FDA review, waiting for funding to be released | Funding |
| NCT06250036 | Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer(ZODIAC) | Phase 2 | suspended | Feb 8, 2024 | Royal Marsden NHS Foundation Trust | Gilead's ongoing evaluation of the wider Zimberelimab and Domvanalimab programme, following the… | Safety / toxicity |
| NCT05514717 | A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 | Phase 1 | terminated | Aug 24, 2022 | Day One Biopharmaceuticals, Inc. | Development discontinued. | Other (stated, no rule matched) |
| NCT04034251 | Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for… | Phase 2 | terminated | Jul 26, 2019 | National Cancer Institute (NCI) | Scientific reprioritization. Closed per principal investigator discretion to prioritize enrollment… | Investigator |
| NCT04929015 | Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES… | N/A | suspended | Jun 18, 2021 | Rutgers, The State University of New Jersey | Pending Protocol amendment | Other (stated, no rule matched) |
| NCT05567835 | A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in…(TOGAR) | Phase 2 | terminated | Oct 5, 2022 | Baylor College of Medicine | Since activation, 3 subjects were enrolled but were ineligible for randomization to a treatment arm… | Enrollment / accrual |
| NCT02366819 | Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating… | Phase 4 | suspended | Feb 19, 2015 | University of Chicago | Pending data analysis | Other (stated, no rule matched) |
| NCT06560645 | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic… | Phase 1 | terminated | Aug 19, 2024 | Prelude Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT07283848 | Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma | Phase 2 | withdrawn | Dec 16, 2025 | Massachusetts General Hospital | The pharmaceutical company is not moving forward with this intervention due to lack of efficacy. | Efficacy / futility |
| NCT03042169 | Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage…(SURGIGAST) | Phase 3 | terminated | Feb 3, 2017 | University Hospital, Lille | default inclusion | Other (stated, no rule matched) |
| NCT04779151 | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and…(NIRADO) | Phase 2 | terminated | Mar 3, 2021 | Gustave Roussy, Cancer Campus, Grand Paris | Abandon of the partner, GSK | Other (stated, no rule matched) |
| NCT04363801 | A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With…(DisTinGuish) | Phase 2 | terminated | Apr 27, 2020 | Leap Therapeutics, Inc. | experimental treatment will not be more efficacious than its comparator in the primary endpoint of… | Other (stated, no rule matched) |
| NCT06264921 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | terminated | Feb 20, 2024 | NiKang Therapeutics, Inc. | This study was terminated as a result of Sponsor portfolio reprioritization. | Sponsor / business decision |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Mar 7, 2024 | Numab Therapeutics AG | Business decision | Sponsor / business decision |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT06728657 | Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric…(TORCH-G) | Phase 2 | suspended | Dec 11, 2024 | Fudan University | Difficult in recruiting participants | Enrollment / accrual |
| NCT04727151 | TAC T-cells for the Treatment of HER2-positive Solid Tumors(TACTIC-2) | Phase 1 / Phase 2 | terminated | Jan 27, 2021 | Triumvira Immunologics, Inc. | Study terminated by Sponsor for commercial reasons | Other (stated, no rule matched) |
| NCT05311176 | A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in…(nextHERIZON) | Phase 2 | terminated | Apr 5, 2022 | Imugene Limited | Study was discontinued because of slow enrollment and organizational priorities and not because of… | Safety / toxicity |
| NCT05166577 | Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With… | Phase 1 | terminated | Dec 22, 2021 | Viracta Therapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04032704 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | Phase 2 | terminated | Jul 25, 2019 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT04213794 | Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for…(TOASTIT) | Early Phase 1 | terminated | Dec 30, 2019 | Mayo Clinic | slow accrual | Enrollment / accrual |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | Phase 1 | terminated | Feb 5, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT05296005 | Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers | Phase 1 | withdrawn | Mar 25, 2022 | Ohio State University Comprehensive Cancer Center | PI Decision | Other (stated, no rule matched) |
| NCT06702384 | Molecular Analysis of Gastric and OEsophageal Cancers STudy(MAGnET) | — | withdrawn | Nov 25, 2024 | Royal Marsden NHS Foundation Trust | Never opened to recruitment due to lack of funding | Enrollment / accrual |
| NCT02485834 | FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced… | Phase 2 | terminated | Jun 30, 2015 | Alliance for Clinical Trials in Oncology | Poor accrual | Enrollment / accrual |
| NCT04162665 | Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer | Phase 2 | terminated | Nov 14, 2019 | Washington University School of Medicine | Poor accrual and funding sponsor declared bankruptcy. | Enrollment / accrual |
| NCT05555251 | BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid…(CONTRAST) | Phase 1 / Phase 2 | terminated | Sep 26, 2022 | BioInvent International AB | After the completion of phase IA, for business reasons it was decided to terminate the study. | Sponsor / business decision |
| NCT05056805 | An Exercise and Nutrition Monitoring Intervention (Pt Pal) for the Improvement of… | N/A | withdrawn | Sep 27, 2021 | M.D. Anderson Cancer Center | No participants enrolled. | Enrollment / accrual |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors…(PDL1x41BB) | Phase 1 | terminated | Jan 18, 2019 | Inhibrx Biosciences, Inc | Program terminated due to lack of meaningful efficacy signal. | Efficacy / futility |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | Phase 2 | terminated | Aug 19, 2021 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT04931420 | Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive… | Phase 2 | withdrawn | Jun 18, 2021 | University of Chicago | PI left site | Investigator |
| NCT01034670 | Advanced Gastrointestinal Endoscopic Imaging | N/A | terminated | Dec 17, 2009 | Stanford University | Change in personnel and cessation of funding | Funding |
| NCT04604132 | Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in…(FIDES-03) | Phase 1 / Phase 2 | terminated | Oct 27, 2020 | Basilea Pharmaceutica | Terminated prematurely for administrative reasons not related to patient safety. | Safety / toxicity |
| NCT05687617 | Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases for… | Phase 2 | terminated | Jan 18, 2023 | Laval University | Recruitment lower than expected and negative results. | Enrollment / accrual |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With… | Phase 1 | terminated | Dec 23, 2020 | Ikena Oncology | Sponsor business decision. | Sponsor / business decision |
| NCT04718402 | A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced… | Phase 1 | terminated | Jan 22, 2021 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | The sponsor has adjusted its R\&D strategy. | Sponsor / business decision |
| NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine… | Phase 1 | withdrawn | Oct 26, 2020 | QuantumLeap Healthcare Collaborative | Study withdrawn as scientific interest in pursuing the SYD985+Paclitaxel combination has diminished. | Other (stated, no rule matched) |
| NCT04977401 | EndoscoPic Submucosal dIssection Using geL Versus glycerOl for Submucosal iNjection(EPSILON) | N/A | terminated | Jul 26, 2021 | Erasme University Hospital | Urgent Medical Device Product (ORISE Gel Submucosal Liftiong Agent) Removal by sponsor | Other (stated, no rule matched) |
| NCT03722108 | Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic…(REGIRI) | Phase 1 / Phase 2 | terminated | Oct 26, 2018 | UNICANCER | Unfavorable benefit-risk balance in the experimental arm following the IDMC for intermediate… | Safety / toxicity |
| NCT02344810 | C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating… | Phase 1 / Phase 2 | withdrawn | Jan 26, 2015 | Eastern Cooperative Oncology Group | The study did not open to accrual. No start date and no completion dates. | Enrollment / accrual |
| NCT04650451 | Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects… | Phase 1 | suspended | Dec 2, 2020 | Bellicum Pharmaceuticals | Due to a Dose Limiting Toxicity in another sister trial with same technology. | Safety / toxicity |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and…(MATILDA) | Phase 2 | withdrawn | Jun 11, 2019 | Gustave Roussy, Cancer Campus, Grand Paris | Similar clinical trials showed not very encouraging results, which made us decide, after several… | Other (stated, no rule matched) |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
| NCT05091528 | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies… | Phase 1 / Phase 2 | terminated | Oct 25, 2021 | Silverback Therapeutics | Sponsor decision based on strategic re-alignment | Sponsor / business decision |
| NCT03735290 | A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors…(ILIAD) | Phase 1 | terminated | Nov 8, 2018 | Mendus | Decision made not to move to Phase 2 | Other (stated, no rule matched) |
| NCT05001360 | Study of FMT Combined With Nivolumab in Gastric Cancer | N/A | withdrawn | Aug 11, 2021 | Fujian Cancer Hospital | We could not get the IRB approval. | Other (stated, no rule matched) |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | Phase 1 | terminated | Sep 23, 2019 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in… | Phase 1 / Phase 2 | withdrawn | Jul 9, 2020 | NKGen Biotech, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT00064259 | A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal… | Phase 1 / Phase 2 | terminated | Jul 9, 2003 | National Cancer Institute (NCI) | Discontinued development of G3139 (oblimersen) | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials